Olaparib 100 mg, 150 mg Suppliers & Bulk Manufacturers

Available Forms: Tablet

Available Strengths: 100 mg, 150 mg

Reference Brands: Lynparza® (US & EU)

Category: Oncology Cancer Care

Olaparib Tablets (brand: Lynparza®) are oral PARP inhibitors for ovarian, breast, pancreatic, and prostate cancers, especially in BRCA-mutated cases. Available in 100 mg and 150 mg, and approved in the US and EU, Olaparib offers a reliable, GMP-compliant oncology solution for global B2B pharmaceutical distribution.

Product Description: Olaparib Tablets, sold under the brand name Lynparza®, are oral PARP inhibitors used in treating advanced ovarian, breast, pancreatic, and prostate cancers, especially in patients with BRCA mutations. Olaparib interferes with cancer cell DNA repair, enhancing cell death in tumors with deficient repair mechanisms. Available in 100 mg and 150 mg strengths, these tablets are approved in both the US and EU and manufactured under GMP-certified facilities. As a breakthrough targeted therapy, Olaparib is a valuable option for oncology-focused pharmaceutical partners seeking high-quality, globally compliant formulations for B2B supply in regulated markets.